The market for U.S. viral vector and plasmid DNA manufacturing market is expanding. The market, valued at USD 2,204.51 million in 2023, is poised to reach USD 11,315.21 million by 2032. It is anticipated to register a CAGR of 19.9% from 2024 to 2032.